Guanhao Biotech Co., Ltd. engages in the research, development, production, and sale of regenerative medical materials and implantable medical devices. The company's core product offerings include biological dura mater repair patches such as NormalGEN and GrandNeuro for neurosurgery; surgical patches like ThormalGEN; wound dressing products including DermalGEN for burns and trauma wounds; and specialized products such as IREAL breast patches and Youvision corneal grafts. Additionally, Guanhao produces sterile biological wound membranes, thoracic surgery repair patches, biological dura mater spine patches (Type B dura), artificial lenses, and medical instruments. It also provides advanced cell technology services. These products and services primarily serve medical fields including neurosurgery, thoracic surgery, ophthalmology, dermatology, orthopedics, and cosmetology.
Founded in 1999 and headquartered in Guangzhou, China, Guanhao Biotech primarily operates within the domestic Chinese market. In recent developments, the company continues to expand its regenerative medicine portfolio and life sciences business model, integrating biomaterials, stem cells, pharmaceuticals, and advanced medical technologies into a “3+1” framework encompassing materials, cells, pharmaceuticals, and a technology incubation platform. Recent strategic moves include enhanced focus on innovative drug development, participation in commercial insurance programs for innovative drugs, and international cooperation efforts to promote high-quality pharmaceutical advancements. The company maintains a strong emphasis on expanding its technological platform and product pipeline in the regenerative medicine sector while strengthening its position within China’s medical device marketplace.
Guanhao’s recent product innovation and business expansion efforts align with industry trends toward advanced regenerative medicine and innovative pharmaceutical technologies, supporting growth through strategic partnerships and capital market engagement. This includes ongoing R&D in small molecule drugs, prophylactic and mRNA vaccines, and clinical trial activities. Guanhao Biotech targets patients requiring surgical repair of tissue and organ damage and healthcare institutions across China. The company employs over 500 personnel and positions itself as a key player in regenerative medical device manufacturing with a growing footprint in biotech innovation and cell technology services.